Relay Therapeutics, Inc.

Relay Therapeutics, Inc. achieved a new 52-week high of USD 18.92, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a remarkable growth of 136.79% over the past year, despite being loss-making and not offering dividends, while maintaining a unique financial structure.

Relay Therapeutics, Inc. has achieved a new 52-week high, reflecting a substantial year-over-year stock performance increase. The company, with a market capitalization of USD 1,716 million, operates at a loss and does not pay dividends, while maintaining a unique financial structure within the biotechnology sector.

Relay Therapeutics, Inc. faced a significant stock decline today, reaching an intraday low. Despite this, the company has shown strong annual growth and positive quarterly results, with net sales of USD 10 million. However, it operates with negative cash flow and high institutional ownership.

Relay Therapeutics, Inc. saw a notable increase in its stock price on June 2, 2026, reaching an intraday high of USD 17.46. The company has delivered impressive returns over the past year and year-to-date, despite reporting significant losses. High institutional holdings reflect strong investor confidence.

Relay Therapeutics, Inc. has achieved a new 52-week high, reflecting a substantial increase over the past year and significantly outperforming the S&P 500. The company, with a market capitalization of USD 1,810 million, remains unprofitable, showcasing a notable growth trajectory in the biotechnology sector.

Relay Therapeutics, Inc. has seen notable stock performance, with significant gains over the past week and month, as well as a remarkable increase over the past year. Despite facing challenges such as high cash flow losses and negative return on equity, the company enjoys strong institutional ownership, reflecting investor confidence.

Relay Therapeutics, Inc. has achieved a new 52-week high, reflecting significant growth from its previous low. The company, with a market capitalization of USD 1,508 million, operates in the Pharmaceuticals & Biotechnology sector and is noted for its unique financial structure, focusing on growth and reinvestment.

Relay Therapeutics, Inc. has experienced significant stock price fluctuations, currently priced at $10.26. The company has shown notable volatility over the past year, with a high of $11.43 and a low of $1.77. Its performance has outpaced the S&P 500, achieving a return of 215.69%.

Relay Therapeutics, Inc. achieved a new 52-week high of USD 7.64 on October 29, 2025, significantly up from its previous low of USD 1.78. Despite this milestone, the company has seen a 1-year performance decline, operates in the Pharmaceuticals & Biotechnology sector, and has a market cap of around USD 700 million.

Relay Therapeutics, Inc. achieved a new 52-week high of USD 7.50 on October 24, 2025, despite a 1-year performance decline of 8.9%. The company, with a market capitalization of approximately USD 700 million, remains loss-making and does not offer dividends, reflecting its microcap status.

Relay Therapeutics, Inc. experienced a notable increase in stock performance on October 15, 2025, reaching an intraday high. The company has outperformed the S&P 500 over various periods, although it faces long-term challenges with significant declines in performance metrics and ongoing financial pressures.

Relay Therapeutics, Inc. has experienced notable shifts in its technical indicators, with current trading reflecting a mixed performance. Despite recent fluctuations, the company has struggled significantly over the past year, with stock returns declining sharply compared to the S&P 500, indicating ongoing challenges in the market.